Autoplaque vs Aorta-CAD
AI Verdict
Choose Autoplaque if…
Choose Autoplaque if your clinical workflow requires detailed, quantitative analysis of coronary plaques and luminal stenoses from CT angiography images. This tool is ideal for cardiologists and radiologists needing precise measurements and characterization of coronary artery disease to inform heart attack risk prediction and guide treatment strategies.
View Autoplaque →Choose Aorta-CAD if…
Choose Aorta-CAD if you need an AI-powered assistant for screening and detecting signs of Aortic Atherosclerosis and Aortic Ectasia on standard chest X-rays. This cloud-based solution is particularly useful for improving the accuracy and immediacy of frontline diagnostic imaging in settings where chest X-rays are a primary diagnostic tool, such as primary care or high-volume radiology departments.
View Aorta-CAD →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Autoplaque | Aorta-CAD |
|---|---|---|
| Deployment | Workstation-based post-processing application, runs on Windows or Mac OS. | Cloud-based software that integrates into existing chest X-ray workflows and Picture Archiving and Communication System (PACS) viewers. |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Unknown | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Aorta-CADTool B (Aorta-CAD) is cloud-based and designed for seamless integration into existing X-ray reading workflows, which generally offers greater accessibility and lower IT overhead. Its annotation overlay can be toggled on/off, suggesting a non-disruptive user experience. Tool A (Autoplaque), being workstation-based, may require more setup and maintenance, potentially limiting its overall ease of use across an enterprise.
Clinical Value
AutoplaqueTool A (Autoplaque) provides sophisticated quantitative analysis of coronary plaques and luminal stenoses from CT angiography, directly aiding in heart attack risk prediction and treatment guidance. While Tool B (Aorta-CAD) demonstrates a significant reduction in misses for aortic conditions on chest X-rays, Tool A's detailed, quantitative assessment from advanced imaging offers a deeper level of clinical insight for high-stakes cardiovascular decision-making.
Pricing & Value
TieBoth Tool A (Autoplaque) and Tool B (Aorta-CAD) have undisclosed pricing, with both requiring direct contact for pricing information. Without any transparency on cost, it is impossible to conduct a meaningful comparison of their pricing or assess their value proposition.
Enterprise Readiness
Aorta-CADTool B (Aorta-CAD) explicitly states it is HIPAA compliant and has a Business Associate Agreement (BAA), which are critical requirements for healthcare enterprises. Its cloud-based deployment also simplifies large-scale integration and management. Tool A (Autoplaque) lacks explicit statements on HIPAA compliance and BAA, and its workstation-based deployment could present more challenges for enterprise-wide implementation and IT management.
Innovation
AutoplaqueTool A (Autoplaque) demonstrates a higher degree of innovation by offering AI-powered quantitative analysis of coronary plaques and luminal stenoses from CT angiography. This goes beyond simple detection to provide detailed, measurable insights crucial for risk stratification. While Tool B (Aorta-CAD) innovatively applies deep learning to chest X-rays for aortic conditions, Tool A's depth of quantitative analysis in a complex imaging modality represents a more advanced application of AI in cardiology.
Support & Docs
TieNeither the provided structured facts nor readily available public information from web searches offer details regarding the availability of support channels, documentation, or service level agreements for Tool A (Autoplaque) or Tool B (Aorta-CAD). Consequently, it is not possible to distinguish between the two on this dimension.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Autoplaque | Aorta-CAD |
|---|---|---|
| Name | Autoplaque | Aorta-CAD |
| Company | Cedars-Sinai Medical Center: AIM | Imagen Technologies |
| Description | Autoplaque, developed by Cedars-Sinai AIM, is an FDA-cleared AI-powered software for quantitative analysis of coronary plaques and luminal stenoses from CT angiography images, aiding in heart attack risk prediction and treatment guidance. | Aorta-CAD by Imagen Technologies is an FDA-cleared, cloud-based AI software that assists physicians in detecting signs of Aortic Atherosclerosis and Aortic Ectasia on chest X-rays, integrating seamlessly into existing workflows. |
| Imaging Modality | CT Angiography images | Chest X-rays |
| Key Analysis Focus | Coronary plaques and luminal stenoses | Aortic Atherosclerosis and Aortic Ectasia |
Videos
Demos, reviews, and walkthroughs featuring Autoplaque and Aorta-CAD.